Target Name: OPCML
NCBI ID: G4978
Review Report on OPCML Target / Biomarker Content of Review Report on OPCML Target / Biomarker
OPCML
Other Name(s): Opioid-binding protein/cell adhesion molecule (isoform b) | Opioid-binding protein/cell adhesion molecule | opioid binding protein/cell adhesion molecule-like preprotein | Opioid-binding cell adhesion molecule | IgLON family member 1 | IGLON1 | OPCM_HUMAN | Opioid binding protein/cell adhesion molecule like, transcript variant 2 | OBCAM | OPCM | opioid-binding protein/cell adhesion molecule | opioid binding protein/cell adhesion molecule like | OPCML variant 2

OPCML: A Protein Involved in Pain, Cancer and Brain Development

OPCML, or Opioid-binding protein/cell adhesion molecule (isoform b), is a protein that is expressed in various tissues throughout the body, including the brain, nervous system, and immune system. It is a member of the immunoglobulin superfamily and is characterized by its ability to interact with opiates, which are drugs that affect the brain and nervous system.

The OPCML protein is involved in the regulation of a variety of physiological processes in the body, including pain perception, inflammation, and immune responses. It is also involved in the development and maintenance of tissues, including the brain and nervous system.

Recent studies have suggested that OPCML may be a drug target or biomarker for various diseases, including cancer, anxiety, and depression. This is because the OPCML protein has been shown to play a role in the development and progression of these diseases, and may also be involved in their treatment.

One of the potential reasons why OPCML may be a drug target is its involvement in pain perception. OPCML has been shown to play a role in the regulation of pain signaling in the brain, and may be involved in the development of chronic pain. Studies have shown that OPCML levels are often reduced in individuals with chronic pain, and that inhibiting OPCML activity may be an effective way to treat pain.

Another potential reason why OPCML may be a drug target is its involvement in the development and progression of cancer. OPCML has been shown to promote the growth and survival of cancer cells, and may also play a role in their metastasis. Studies have shown that OPCML levels are often increased in various types of cancer, and that inhibiting OPCML activity may be an effective way to treat these diseases.

In addition to its involvement in pain perception and cancer development, OPCML may also be involved in the regulation of inflammation. OPCML has been shown to play a role in the regulation of inflammation in the body, and may be involved in the development of inflammatory diseases.

The OPCML protein is also involved in the development and maintenance of tissues, including the brain and nervous system. Studies have shown that OPCML levels are often reduced in individuals with neurodegenerative diseases, and that inhibiting OPCML activity may be an effective way to treat these diseases.

In conclusion, OPCML is a protein that is expressed in various tissues throughout the body and is involved in the regulation of a variety of physiological processes in the body. Recent studies have suggested that OPCML may be a drug target or biomarker for various diseases, including cancer, anxiety, and depression. Further research is needed to fully understand the role of OPCML in these diseases and to develop effective treatments.

Protein Name: Opioid Binding Protein/cell Adhesion Molecule Like

Functions: Binds opioids in the presence of acidic lipids; probably involved in cell contact

The "OPCML Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OPCML comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OPHN1 | Opioid receptor | OPLAH | OPN1LW | OPN1MW | OPN1MW3 | OPN1SW | OPN3 | OPN4 | OPN5 | OPRD1 | OPRK1 | OPRL1 | OPRM1 | OPRPN | OPTC | OPTN | OR10A2 | OR10A3 | OR10A4 | OR10A5 | OR10A6 | OR10A7 | OR10AA1P | OR10AB1P | OR10AC1 | OR10AD1 | OR10AF1P | OR10AG1 | OR10AK1P | OR10C1 | OR10D1P | OR10D3 | OR10D4P | OR10G2 | OR10G3 | OR10G4 | OR10G7 | OR10G8 | OR10G9 | OR10H1 | OR10H2 | OR10H3 | OR10H4 | OR10H5 | OR10J1 | OR10J2P | OR10J3 | OR10J5 | OR10K1 | OR10K2 | OR10P1 | OR10Q1 | OR10R2 | OR10S1 | OR10T2 | OR10V1 | OR10W1 | OR10X1 | OR10Z1 | OR11A1 | OR11G2 | OR11H1 | OR11H12 | OR11H13P | OR11H2 | OR11H5P | OR11H6 | OR11H7 | OR11J2P | OR11J5P | OR11K2P | OR11L1 | OR11M1P | OR12D2 | OR12D3 | OR13A1 | OR13C2 | OR13C3 | OR13C4 | OR13C5 | OR13C8 | OR13C9 | OR13D1 | OR13F1 | OR13G1 | OR13H1 | OR13J1 | OR13Z2P | OR14A16 | OR14A2 | OR14C36 | OR14I1 | OR14J1 | OR14L1P | OR1A1 | OR1A2 | OR1B1 | OR1C1 | OR1D2